Big Step for Nano Technology

• Share
• E-mail
• Print

Nanoemulsion technology has taken one step closer to the market, with the announcement of a new licensing agreement between NanoBio, developer of the technology, and GlaxoSmthKline. The two companies have signed an exclusive over-the-counter licensing agreement for NanoBio’s nanoemulsion treatment, NB-001 for cold sores in the US and Canada. Under the agreement, GSK will pay NanoBio $14.5 million for licensing rights to NB- 001. NanoBio is eligible to receive additional milestone payments plus royalties on future sales.

Click here for more industry news and clinical trial updates.

Comment on this Article:

You must be logged in to leave a comment.

TOP 5 ARTICLES FROM 2010

• Technology Connection: EMR Meets Modern Technology

  Touch-screen technology may offer multiple benefits for adoption and effective use of EMRs.

  By Michael Sherling, MD

• Recent Developments: What’s Next for the Dermatology Pharmaceutical Industry?

  No doubt the dermatology pharmaceutical industry is undergoing a change. But what does it mean?

• Dermatology Q&A: New Directions in the Treatment of Hypopigmented Scars

  A new study shows that off-label use of an unexpected agent yields promising results in the repigmentation of hypopigmented scars.

  By Ted Pigeon, Senior Associate Editor

• Epidermal Barrier Dysfunction: Beyond Atopic Dermatitis

  Specialists describe how a disrupted barrier contributes to common dermatoses and offer strategies for treatment.

  By Joseph Bikowski, MD and Matthew Zirwas, MD

• Therapeutics Update

  Product News